Home
Learn More
Search Archives
Business Wire News
Business Wire Services
September 6, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
ViewNews™  
RSS  
EON: Enhanced Online News. Powerful technology and tools to help optimize your news content and enhance online visibility for major search engines.
A key component to your social networking and viral marketing strategy. In partnership with industry leader PRWeb.
 
All Press Releases for May 27, 2008 Subscribe to this News Feed      
 

Polymer Technology Group (PTG) to Report Self-Assembling, Antimicrobial End Groups for Surface Modification of Biomedical Polymers

Results of initial testing of an important new technology to be presented this week at 8th World Biomaterials Congress, Amsterdam

Our demonstration of the self-assembly of an effective antimicrobial agent bonded to a polymer before device fabrication provides a low-cost alternative to biocidal coatings for reducing device-related infections. -Robert S. (Bob) Ward, CEO, Polymer Technology Group (PTG)

BERKELEY, Calif. (Business Wire EON) May 27, 2008 -- The Polymer Technology Group, Inc. (www.polymertech.com), a preeminent biomaterials company, announced today that Shanger Wang, Ph.D., will report from the podium this week during the 8th World Biomaterials Congress in Amsterdam, The Netherlands. His presentation (Thermoplastic Polycarbonate-Urethane with Surface-Active Alkylammonium Chloride End Groups: Antimicrobial Activity, Bulk and Surface Properties) will include the characterization of a breakthrough polymeric biomaterial with permanently-bonded antimicrobial surface properties designed to reduce medical device-centered infection. PTG is also exhibiting at the conference (booth #5).

Thermoplastic Polycarbonate-Urethane with Surface-Active Alkylammonium Chloride End Groups: Antimicrobial Activity, Bulk and Surface Properties
The device industry has been challenged to produce polymeric biomaterials with built-in antimicrobial surface properties for reducing device-centered infection. But most approaches to date have used drug-eluting compounds or coatings that are eventually consumed. It is much more desirable to have easily processed biomaterials with good wet-strength and long-term efficacy without leachable additives, drugs or biocides, said Bob Ward, CEO. We believe we have an answer to this problem.

News Image Indeed, the results being presented by Dr. Wang demonstrate that very small amounts of biologically active end-groups can be permanently incorporated into a polymeric biomaterial during its synthesis, added Ward. The novelty here is that after extrusion or molding, the device modifies its own surface because of the surface activity and self assembly of the novel end-groups. Antimicrobial groups concentrate in the surface where they are needed. For this reason secondary coating processes or treatments are not needed. This can reduce the cost of goods and manufacturing times while increasing yield.

Dr. Wang will report that polyurethanes with surface-active alkylammonium chloride end-groups were successfully synthesized and their physical properties, surface chemistry and biocidal activities evaluated. The presence and self assembly of end-groups in the surface was confirmed by SFG (Sum Frequency Generation Spectroscopy). The polymers exhibit low water absorption, excellent strength and processability, high molecular weight, and effective contact-killing of Gram-positive bacteria relative to controls. Dr. Wang will also discuss how these modified TPCUs (Thermoplastic PolyCarbonate Urethanes) and polymers with other antimicrobial self-assembling monomer end groups are currently being optimized by PTG for use in various biomedical applications.

ABOUT PTG

Headquartered in Berkeley, Calif., The Polymer Technology Group, Inc. (PTG) specializes in the research, development, design, scale-up, and manufacture of new polymers, medical devices, and components. PTG's recently expanded operations to 70,000-square-feet comprise the equipment and expertise to support production-scale polymer synthesis through contract medical device manufacturing. On April 28th the company announced it has agreed to be acquired by DSM, the global Life Sciences and Materials Sciences company headquartered in the Netherlands. The union with PTG will enable DSM Biomedical to expand its unique portfolio of materials-based technologies which will benefit customers in the medical device and pharmaceutical industries. Closing of the acquisition is expected to take place by the end of May, 2008.

Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/Q291cC1Db3VwLUZhbHUtRmFsdS1DcmFzLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION

Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files by creating a Smart News Release at Business Wire.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases, please contact the company listed in the press release (see "Contact Information" in the right hand navigation panel). Please do not contact Business Wire or PRWeb®, as we will be unable to assist you with your inquiry.

Business Wire and PRWeb® disclaim responsibility for all content contained in these releases. Our complete disclaimer appears here.
 

About Us   |   Contact Us   |   Privacy Statement   |   Terms of Use (Updated)   |   © Business Wire 2006